The Indian Journal of Pediatrics

, Volume 69, Issue 2, pp 169–173 | Cite as

Ascites and encephalopathy in chronic liver disease

Symposium on Hematology-II
  • 93 Downloads

Abstract

Ascites and particularly encephalopathy in the setting of chronic liver disease are traditionally thought to be poor prognostic markers of end stage liver disease. Diagnostic and therapeutic approaches to these complications are based on experience with adult patients, however, differences in the spectrum of aetiologies causing end stage liver disease together with the relative resistance of the pediatric patient to encephalopathy impact on the management of such patients. The following is a review of current thinking in the aetiology and management of ascites and encephalopathy in the setting of chronic liver disease in children.

Key words

Ascites Encephalopathy Children Liver failure Liver transplantation 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Morali GA, Snideramn KW, Deitel KMet al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?J Hepatol 11992; 16 : 249–250.Google Scholar
  2. 2.
    Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites and spontaneous bacterial peritonitis.Gastroenterology 2001; 120: 726–748.PubMedCrossRefGoogle Scholar
  3. 3.
    Rossle M, Ochs A, Golberg Vet al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.N Engl J Med 2000; 342: 1701–1707.PubMedCrossRefGoogle Scholar
  4. 4.
    Garcia-Tsao G. Treatment of refractory ascites: tips or taps?Hepatology 2001; 33: 477–479.PubMedCrossRefGoogle Scholar
  5. 5.
    Heyman MB, LaBerge JM. Role of transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension in pediatric patients.J Ped Gastro Nutr 1999; 29: 240–249.CrossRefGoogle Scholar
  6. 6.
    Rimola A, Garcia-Tsao G, Navasa M, Piddock V, Planas R, Bernard Bet al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document.J Hepatol 2000; 32: 142–153.PubMedCrossRefGoogle Scholar
  7. 7.
    Gines P, Rimola A, Planas R, Vargas V, Marco F, Almale M. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial.Hepatology 1990; 12: 716–724.PubMedCrossRefGoogle Scholar
  8. 8.
    Jones EA. Pathogenesis of hepatic encephalopathy.Clinics in Liver Dis 2000; 4: 467–485.CrossRefGoogle Scholar
  9. 9.
    Albrecht J, Dolinska M. Glutamine as a pathogenic factor in hepatic encephalopathy.J Neuroscience Res 2001; 65: 1–5.CrossRefGoogle Scholar
  10. 10.
    Sand P., Kawadias D, Feineis Det al. Naturally occurring benzodiazepines:current status of research and clinical implications.Eur Arch Psych Clin Neuroscience 2000; 250: 194–202.CrossRefGoogle Scholar
  11. 11.
    Watanabe A. Cerebral changes in hepatic encephalopathy.J Gastroenterol Hepatol 1998; 13: 752–760.PubMedCrossRefGoogle Scholar
  12. 12.
    Weber Fl Jr. Lactulose and combination therapy of hepatic encephalopathy: the role of intestinal microflora.Dig Dis 1996 14: 53–63.PubMedGoogle Scholar
  13. 13.
    Scevola D, Zarmelli A, Concia Eet al. Non-absorbable disaccharides plus neomycin in hepatic encephalopathy: do they enhance each other?La Clinica Terapeutica 1989; 129: 105–111.PubMedGoogle Scholar
  14. 14.
    Marchesini G, Bianchi G, Rossi B, Brizi M, Melchionda N. Nutritional treatment with branched-chain amino-acids in advanced liver cirrhosis.J Gastroenterol 2000; 35: 7–12.PubMedGoogle Scholar
  15. 15.
    Charlton CPJ, Buchanan E, Holden CEet al. Intensive enteral feeding in advanced cirrhosis: reversal of malnutrition without precipitation of hepatic encephalopathy.Arch Dis Child 1992; 67: 603–607.PubMedCrossRefGoogle Scholar
  16. 16.
    D’Amico G, Morabito A, Pagliaro Let al. Survival and prognostic indicators in compensated and decompensated cirrhosis.Dig Dis Sci 1986; 31: 468–475.PubMedCrossRefGoogle Scholar
  17. 17.
    Matalack J, Shaid D, Urback Aet al. Choosing a pediatric recipient for orthotopic liver transplantation.J Pediatr 1987; 111: 479–489.CrossRefGoogle Scholar
  18. 18.
    Wayman KI, Cox KL, Esquivel CO Neuro-developmental outcome of young children with extrahepatic biliary atresia 1 year after liver transplantation.J Pediatr 1997; 131: 894–894.PubMedCrossRefGoogle Scholar
  19. 19.
    Bhaduri RR, Mieli-Vergani G. Fulminant hepatic failure: Pediatric aspects. SeminLiver Dis 1996; 16: 349–355.Google Scholar
  20. 20.
    Hartmann U, Groeneweg M, Quero JCet al. The prognostic significance of subclinical hepatic encephalopathy.Am J Gastro 2000; 95: 2029–2034.CrossRefGoogle Scholar
  21. 21.
    Kamath PS, Wiesner RH, Malinchoc Met al. A model to predict survival in patients with end-stage liver disease.Hepatology 2001; 33: 464–470.PubMedCrossRefGoogle Scholar
  22. 22.
    Gitlin N. Hepatic encephalopathy. In Zakim D, Boyer M, eds.Hepatology: A Textbook of Liver Disease. 3rd edn. Philadelphia: W.B. Saunders, 1996; 12: 605–617.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2002

Authors and Affiliations

  1. 1.Dept. of GastroenterologyRoyal Children’s HospitalParkvilleAustralia

Personalised recommendations